US 7,414,050 B2
Inhibitors of c-fms kinase
Carl R. Illig, Phoenixville, Pa. (US); Shelly K. Ballentine, Lansdale, Pa. (US); Jinsheng Chen, Exton, Pa. (US); Renee Louise DesJarlais, Saint Davids, Pa. (US); Sanath K. Meegalla, Boothwyn, Pa. (US); Mark Wall, Flourtown, Pa. (US); and Kenneth Wilson, Media, Pa. (US)
Assigned to Janssen Pharmaceutica, N.V., Beerse (Belgium)
Filed on Apr. 18, 2007, as Appl. No. 11/736,617.
Claims priority of provisional application 60/793697, filed on Apr. 20, 2006.
Claims priority of provisional application 60/883539, filed on Jan. 05, 2007.
Prior Publication US 2007/0249593 A1, Oct. 25, 2007
Int. Cl. C07D 417/04 (2006.01); C07D 417/14 (2006.01); A61K 31/541 (2006.01)
U.S. Cl. 514—222.5  [544/5; 544/8] 16 Claims
 
1. A compound of Formula I:

OG Complex Work Unit Drawing
wherein:
W is

OG Complex Work Unit Drawing
 wherein R4=H, F, Cl, Br, I, OH, OCH3, OCH2CH3, —C(1-3)alkyl, —CO2R5, CONR6R7, C≡CR8, or CN;
wherein R5=H, or —C(1-3)alkyl;
R6=H, or —C(1-3)alkyl;
R7=H, or —C(1-3)alkyl; and
R8=H, —CH2OH, or —CH2CH2OH;
R2 is cycloalkyl, spiro-substituted cycloalkenyl, heterocyclyl, spiro-substituted piperidinyl, thiophenyl, dihydrosulfonopyranyl, phenyl, furanyl, tetrahydropyridyl, or dihydropyranyl, any of which may be independently substituted with one or two of each of the following: chloro, fluoro, hydroxy C(1-3)alkyl, and C(1-4)alkyl;
X is selected from the group consisting of:

OG Complex Work Unit Drawing
wherein R1 and R10 are independently H, —CH3, or —C2-C5 alkyl, optionally substituted with one or two of: Me, Et, OH, NH2, NHMe, NMe2, NHEt, NEt2, pyrrolidinyl, pyridyl, morpholino, CONH2, or COOH and such that when any two heteroatoms are attached to said C2 to C5 alkyl group there exists at least two carbon atoms between them, and
Z is H, F, Cl, Br, C1-C3 alkyl or —CH2OH; and
J is CH or N; or
a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof.